CD274 and pancreatic neoplasm: Consistently, zosuquidar reduced PD‐L1 expression under both basal and inducible conditions in NSCLC (NCI‐H1975), ovarian cancer (SKOV3), renal carcinoma (786‐O), and pancreatic cancer (MIA PaCa‐2) (Figure 1C).